Analysts at RBC Capital raised their price target on Amgen Inc. (NASDAQ:AMGN) to $218 from $216, maintaining their sector perform rating to reflect the early approval of Tezspire (tezepelumab) into severe asthma & Otezla’s label expansion into mild-to-moderate plaque psoriasis.

The analysts see both approvals as notable with Tezspire’s broad label making it the only biologic without phenotype or biomarker limitations and Otezla’s label expansion to include mild-to-moderate plaque psoriasis patients making it the first and only oral therapy indicated across all psoriasis severity levels.